文献速递膀胱癌与上尿路尿路上皮癌

肌层浸润性膀胱癌放化疗与根治性膀胱切除术的倾向匹配生存比较

Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer.
PubMed 文献 · BJU Int · 2018-01-22

放化疗在治疗后1年死亡率较低(HR 0.84,95%CI 0.74-0.96,P=0.01),但2年(HR 1.4,95%CI 1.2-1.6,P<0.001)及3年以上(HR 1.5,95%CI 1.2-1.8,P<0.001)死亡率增加;根治性膀胱切除术的5年总生存率更高(38% vs 30%,P=0.004)。

要点

  • 倾向匹配后放化疗1年死亡率低于根治性膀胱切除术(HR 0.84,95%CI 0.74-0.96,P=0.01)。
  • 放化疗2年(HR 1.4,95%CI 1.2-1.6,P<0.001)及3年以上(HR 1.5,95%CI 1.2-1.8,P<0.001)死亡率增加。
  • 根治性膀胱切除术5年总生存率高于放化疗(38% vs 30%,P=0.004)。

核心结论

  • 肌层浸润性膀胱癌治疗后初期放化疗死亡率低于根治性膀胱切除术,但≥2年后死亡率风险倾向于根治性膀胱切除术。
  • 适合手术且并发症风险低的患者可能更适合根治性膀胱切除术。

研究设计与样本

  • 回顾性分析美国国家癌症数据库(2004-2013)中肌层浸润性膀胱癌(≥cT2,N0,M0)患者。
  • 放化疗定义为放疗剂量≥40 Gy且在放疗90天内接受化疗。

主要发现

  • 多变量扩展Cox分析显示,总生存率降低的显著预测因素包括年龄、Charlson-Deyo合并症评分1、Charlson-Deyo合并症评分2、cT3-4期和尿路上皮组织学。
  • 放化疗与1年死亡率降低相关(HR 0.84,95%CI 0.74-0.96,P=0.01)。
  • 放化疗与2年死亡率增加相关(HR 1.4,95%CI 1.2-1.6,P<0.001)。
  • 放化疗与3年及以上死亡率增加相关(HR 1.5,95%CI 1.2-1.8,P<0.001)。
  • 根治性膀胱切除术5年总生存率高于放化疗(38% vs 30%,P=0.004)。

临床怎么用

  • 对于肌层浸润性膀胱癌,放化疗在治疗后初期死亡率较低,但≥2年后死亡率风险倾向于根治性膀胱切除术。
  • 适合手术且并发症风险低的患者可能更适合根治性膀胱切除术。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare survival outcome between chemoradiation therapy (CRT) and radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). PATIENTS AND METHODS: We conducted a retrospective analysis of patients with MIBC (≥cT2, N0, M0) in the National Cancer Database (2004-2013). CRT was defined as a radiation dose of ≥40 Gy and chemotherapy within 90 days of radiation. Descriptive statistics were used to compare groups. RC and CRT patients were propensity matched. Kaplan-Meier analysis was used to compare overall survival (OS). Multivariable Cox regression was used to determine predictors of survival. RESULTS: In all, 8 379 (6 606 RC and 1 773 CRT) patients met the inclusion criteria and 1 683 patients in each group were propensity matched. On multivariable extended Cox analysis, significant predictors of decreased OS were age, Charlson-Deyo Comorbidity score of 1, Charlson-Deyo Comorbidity score of 2, stage cT3-4, and urothelial histology. CRT was associated with decreased mortality at year 1 (hazard ratio [HR] 0.84, 95% confidence interval [CI] 0.74-0.96; P = 0.01), but at 2 years (HR 1.4, 95% CI 1.2-1.6; P < 0.001) and 3 years onward (HR 1.5, 95% CI 1.2-1.8; P < 0.001) CRT was associated with increased mortality. The 5-year OS was greater for RC than for CRT (38% vs 30%, P = 0.004). CONCLUSIONS: Initially after treatment for MIBC the risk of mortality is lower with CRT compared to RC. However, at ≥2 years after treatment the mortality risk favours RC. Patients who are suitable surgical candidates, with a low risk of morbidity, may be better served by RC.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Ritch CR, Balise R, Prakash NS, et al. Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer. BJU Int. 2018. PMID: 29281848. doi:10.1111/bju.14109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。